Cosmix Molecular Biologicals Gmbh

Bayer Aktiengesellschaft

Gesellschaft Fur Biotechnologische Forschung Gmbh

John Collins

Peter R&ouml;ttgen

Ronald Frank

Hans Fritz

Wolfgang Bruns

Helmut Blocker

Friedhelm Maywald

Peter Roettgen

The invention concerns gene banks and combinatorial derivatives thereof, prepared using phagemid- or phage-display in combination with type IIS restriction enzymes and cosmid packaging; their use for the isolation of ligands, including enzyme inhibitors, agonists and antagonists for receptors, competitive binding peptides to a defined target, diagnostic ligands for diseases and autoimmune syndromes, including surveillance tools for immune status, post-translationally modified peptides, and such ligands generated by this technology.

Generation of diversity in combinatorial libraries

The invention concerns a collection of phagemids made up of a promotor, a gene of a fusion between a ligand protein, wherein the ligand protein in its processed state would be of from 40 to 60 amino acid residues, and a bacteriophage protein, at least one transcription terminator sequence, a replication origin derived from a single strand bacteriophage, a plasmid replication origin and facultatively at least one selection marker. Further, the invention concerns a collection of Escherichia coli clones or cells representing the collection of phagemids, a process for isolating phagemid particles with strong binding characteristics for a defined target molecule with the use of collections according to the invention and phagemid particles obtained according to the process.

Phagemids and process of preparation

The present invention relates to a peptide having essentially the amino acid sequence of pancreatic secretory trypsin inhibitor (PSTI). The present invention also relates to variants of such peptide wherein one or more of the amino acids in the original sequence are replaced by other amino acids. These peptides show an advantageously modified specificity in their inhibotory action. A method of preparation of the peptides and their pharmaceutical use is also described.

Pancreatic secretory tryspin inhibitor and variants thereof produced by

Growing community of inventors

Braunschweig, Germany

John Collins